AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDGL
  4. [8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event

[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Madrigal Pharmaceuticals held its 2025 Annual Meeting of Stockholders on June 20, 2025, with 20,427,421 shares represented (92% of outstanding shares), constituting a quorum. Key outcomes include:

  • Board Elections: Four Class III directors were re-elected to serve until 2028, including Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse, and Dr. Richard Levy, with Dr. Fouse receiving the highest approval (18.8M votes)
  • Auditor Appointment: Stockholders ratified PricewaterhouseCoopers LLP as independent auditor with overwhelming support (20.2M votes in favor)
  • Executive Compensation: Shareholders approved named executive officers' compensation with strong support (18.7M votes in favor)
  • Say-on-Pay Frequency: Stockholders strongly favored annual advisory votes on executive compensation (18.8M votes), which the Board has adopted

Madrigal Pharmaceuticals ha tenuto l'Assemblea Annuale degli Azionisti 2025 il 20 giugno 2025, con 20.427.421 azioni rappresentate (92% delle azioni in circolazione), raggiungendo il quorum. I principali risultati sono stati:

  • Elezioni del Consiglio: Quattro direttori di Classe III sono stati rieletti per un mandato fino al 2028, tra cui Julian Baker, il dott. Raymond Cheong, la dott.ssa Jacqualyn Fouse e il dott. Richard Levy, con la dott.ssa Fouse che ha ricevuto il maggior numero di voti favorevoli (18,8 milioni)
  • Nomina del Revisore: Gli azionisti hanno ratificato PricewaterhouseCoopers LLP come revisore indipendente con un ampio consenso (20,2 milioni di voti a favore)
  • Compensi Esecutivi: Gli azionisti hanno approvato la remunerazione dei dirigenti nominati con forte sostegno (18,7 milioni di voti a favore)
  • Frequenza del Say-on-Pay: Gli azionisti hanno fortemente sostenuto votazioni consultive annuali sulla remunerazione esecutiva (18,8 milioni di voti), che il Consiglio ha adottato

Madrigal Pharmaceuticals celebr贸 su Junta Anual de Accionistas 2025 el 20 de junio de 2025, con 20,427,421 acciones representadas (92% de las acciones en circulaci贸n), constituyendo qu贸rum. Los resultados clave incluyen:

  • Elecciones de la Junta: Cuatro directores de Clase III fueron reelegidos para servir hasta 2028, incluyendo a Julian Baker, Dr. Raymond Cheong, Dra. Jacqualyn Fouse y Dr. Richard Levy, siendo la Dra. Fouse la que recibi贸 la mayor aprobaci贸n (18.8 millones de votos)
  • Nombramiento del Auditor: Los accionistas ratificaron a PricewaterhouseCoopers LLP como auditor independiente con un respaldo abrumador (20.2 millones de votos a favor)
  • Compensaci贸n Ejecutiva: Los accionistas aprobaron la compensaci贸n de los ejecutivos nombrados con un fuerte apoyo (18.7 millones de votos a favor)
  • Frecuencia del Say-on-Pay: Los accionistas apoyaron firmemente las votaciones consultivas anuales sobre la compensaci贸n ejecutiva (18.8 millones de votos), lo que la Junta ha adoptado

Madrigal Pharmaceuticals電� 2025雲� 6鞗� 20鞚� 2025雲� 鞐半 欤检＜齑濏殞毳� 臧滌禍頄堨溂氅�, 20,427,421欤�臧� 於滌劃頃橃棳(氚滍枆 欤检嫕鞚� 92%) 鞝曥”靾橁皜 於╈”霅橃棃鞀惦媹雼�. 欤检殧 瓴瓣臣電� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 鞚挫偓須� 靹犾稖: 4氇呾潣 韥措灅鞀� III 鞚挫偓臧� 2028雲勱箤歆� 鞛勱赴毳� 鞙勴暣 鞛劆霅橃棃鞙茧┌, Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse, Dr. Richard Levy臧� 韽暔霅橃棃瓿�, Dr. Fouse臧� 臧�鞛� 毵庫潃 彀劚響�(1,880毵� 響�)毳� 氚涭晿鞀惦媹雼�.
  • 臧愳偓鞚� 靹犾瀯: 欤检＜霌れ潃 PricewaterhouseCoopers LLP毳� 霃呺 臧愳偓鞚胳溂搿� 鞎曤弰鞝侅澑 彀劚(2,020毵� 響�)鞙茧 鞀轨澑頄堨姷雼堧嫟.
  • 瓴届榿歆� 氤挫儊: 欤检＜霌れ潃 歆�氇呺悳 瓴届榿歆� 氤挫儊鞚� 臧曤牓頃� 歆�歆�(1,870毵� 響�)搿� 鞀轨澑頄堨姷雼堧嫟.
  • 氤挫垬鞐� 甏�頃� 甓岅碃 韴憸 牍堧弰: 欤检＜霌れ潃 瓴届榿歆� 氤挫垬鞐� 雽�頃� 鞐瓣皠 甓岅碃 韴憸毳� 臧曤牓頌� 歆�歆�(1,880毵� 響�)頄堨溂氅�, 鞚挫偓須岆姅 鞚措ゼ 毂勴儩頄堨姷雼堧嫟.

Madrigal Pharmaceuticals a tenu son Assembl茅e G茅n茅rale Annuelle des Actionnaires 2025 le 20 juin 2025, avec 20 427 421 actions repr茅sent茅es (92 % des actions en circulation), constituant un quorum. Les r茅sultats cl茅s incluent :

  • 脡lections du Conseil d'Administration : Quatre administrateurs de la classe III ont 茅t茅 r茅茅lus pour un mandat jusqu'en 2028, incluant Julian Baker, Dr Raymond Cheong, Dr Jacqualyn Fouse et Dr Richard Levy, la Dr Fouse ayant re莽u la plus forte approbation (18,8 millions de voix)
  • Nomination de l'Auditeur : Les actionnaires ont ratifi茅 PricewaterhouseCoopers LLP en tant qu'auditeur ind茅pendant avec un soutien 茅crasant (20,2 millions de voix en faveur)
  • R茅mun茅ration des Dirigeants : Les actionnaires ont approuv茅 la r茅mun茅ration des dirigeants nomm茅s avec un fort soutien (18,7 millions de voix en faveur)
  • Fr茅quence du Vote Consultatif sur la R茅mun茅ration : Les actionnaires se sont fortement prononc茅s en faveur de votes consultatifs annuels sur la r茅mun茅ration des dirigeants (18,8 millions de voix), que le Conseil a adopt茅

Madrigal Pharmaceuticals hielt seine Jahreshauptversammlung 2025 am 20. Juni 2025 ab, bei der 20.427.421 Aktien vertreten waren (92 % der ausstehenden Aktien), womit ein Quorum erreicht wurde. Wichtige Ergebnisse sind:

  • Vorstands-Wahlen: Vier Direktoren der Klasse III wurden f眉r eine Amtszeit bis 2028 wiedergew盲hlt, darunter Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse und Dr. Richard Levy, wobei Dr. Fouse die h枚chste Zustimmung erhielt (18,8 Mio. Stimmen)
  • Bestellung des Abschlusspr眉fers: Die Aktion盲re best盲tigten PricewaterhouseCoopers LLP als unabh盲ngigen Abschlusspr眉fer mit 眉berw盲ltigender Mehrheit (20,2 Mio. Stimmen daf眉r)
  • 痴辞谤蝉迟补苍诲蝉惫别谤驳眉迟耻苍驳: Die Aktion盲re genehmigten die Verg眉tung der benannten F眉hrungskr盲fte mit starker Unterst眉tzung (18,7 Mio. Stimmen daf眉r)
  • Say-on-Pay-Frequenz: Die Aktion盲re sprachen sich deutlich f眉r j盲hrliche Beratungsabstimmungen zur Vorstandsverg眉tung aus (18,8 Mio. Stimmen), welche der Vorstand 眉bernommen hat
Positive
  • Strong shareholder support demonstrated with 98.9% approval (18,720,175 votes) for executive compensation package
  • High participation rate with 92% of outstanding shares (20,427,421 shares) represented at Annual Meeting
  • All four Class III directors received strong majority approval, with Dr. Jacqualyn Fouse receiving particularly strong support (99.4% of votes cast)
Negative
  • None.

Insights

Analyzing...

Madrigal Pharmaceuticals ha tenuto l'Assemblea Annuale degli Azionisti 2025 il 20 giugno 2025, con 20.427.421 azioni rappresentate (92% delle azioni in circolazione), raggiungendo il quorum. I principali risultati sono stati:

  • Elezioni del Consiglio: Quattro direttori di Classe III sono stati rieletti per un mandato fino al 2028, tra cui Julian Baker, il dott. Raymond Cheong, la dott.ssa Jacqualyn Fouse e il dott. Richard Levy, con la dott.ssa Fouse che ha ricevuto il maggior numero di voti favorevoli (18,8 milioni)
  • Nomina del Revisore: Gli azionisti hanno ratificato PricewaterhouseCoopers LLP come revisore indipendente con un ampio consenso (20,2 milioni di voti a favore)
  • Compensi Esecutivi: Gli azionisti hanno approvato la remunerazione dei dirigenti nominati con forte sostegno (18,7 milioni di voti a favore)
  • Frequenza del Say-on-Pay: Gli azionisti hanno fortemente sostenuto votazioni consultive annuali sulla remunerazione esecutiva (18,8 milioni di voti), che il Consiglio ha adottato

Madrigal Pharmaceuticals celebr贸 su Junta Anual de Accionistas 2025 el 20 de junio de 2025, con 20,427,421 acciones representadas (92% de las acciones en circulaci贸n), constituyendo qu贸rum. Los resultados clave incluyen:

  • Elecciones de la Junta: Cuatro directores de Clase III fueron reelegidos para servir hasta 2028, incluyendo a Julian Baker, Dr. Raymond Cheong, Dra. Jacqualyn Fouse y Dr. Richard Levy, siendo la Dra. Fouse la que recibi贸 la mayor aprobaci贸n (18.8 millones de votos)
  • Nombramiento del Auditor: Los accionistas ratificaron a PricewaterhouseCoopers LLP como auditor independiente con un respaldo abrumador (20.2 millones de votos a favor)
  • Compensaci贸n Ejecutiva: Los accionistas aprobaron la compensaci贸n de los ejecutivos nombrados con un fuerte apoyo (18.7 millones de votos a favor)
  • Frecuencia del Say-on-Pay: Los accionistas apoyaron firmemente las votaciones consultivas anuales sobre la compensaci贸n ejecutiva (18.8 millones de votos), lo que la Junta ha adoptado

Madrigal Pharmaceuticals電� 2025雲� 6鞗� 20鞚� 2025雲� 鞐半 欤检＜齑濏殞毳� 臧滌禍頄堨溂氅�, 20,427,421欤�臧� 於滌劃頃橃棳(氚滍枆 欤检嫕鞚� 92%) 鞝曥”靾橁皜 於╈”霅橃棃鞀惦媹雼�. 欤检殧 瓴瓣臣電� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 鞚挫偓須� 靹犾稖: 4氇呾潣 韥措灅鞀� III 鞚挫偓臧� 2028雲勱箤歆� 鞛勱赴毳� 鞙勴暣 鞛劆霅橃棃鞙茧┌, Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse, Dr. Richard Levy臧� 韽暔霅橃棃瓿�, Dr. Fouse臧� 臧�鞛� 毵庫潃 彀劚響�(1,880毵� 響�)毳� 氚涭晿鞀惦媹雼�.
  • 臧愳偓鞚� 靹犾瀯: 欤检＜霌れ潃 PricewaterhouseCoopers LLP毳� 霃呺 臧愳偓鞚胳溂搿� 鞎曤弰鞝侅澑 彀劚(2,020毵� 響�)鞙茧 鞀轨澑頄堨姷雼堧嫟.
  • 瓴届榿歆� 氤挫儊: 欤检＜霌れ潃 歆�氇呺悳 瓴届榿歆� 氤挫儊鞚� 臧曤牓頃� 歆�歆�(1,870毵� 響�)搿� 鞀轨澑頄堨姷雼堧嫟.
  • 氤挫垬鞐� 甏�頃� 甓岅碃 韴憸 牍堧弰: 欤检＜霌れ潃 瓴届榿歆� 氤挫垬鞐� 雽�頃� 鞐瓣皠 甓岅碃 韴憸毳� 臧曤牓頌� 歆�歆�(1,880毵� 響�)頄堨溂氅�, 鞚挫偓須岆姅 鞚措ゼ 毂勴儩頄堨姷雼堧嫟.

Madrigal Pharmaceuticals a tenu son Assembl茅e G茅n茅rale Annuelle des Actionnaires 2025 le 20 juin 2025, avec 20 427 421 actions repr茅sent茅es (92 % des actions en circulation), constituant un quorum. Les r茅sultats cl茅s incluent :

  • 脡lections du Conseil d'Administration : Quatre administrateurs de la classe III ont 茅t茅 r茅茅lus pour un mandat jusqu'en 2028, incluant Julian Baker, Dr Raymond Cheong, Dr Jacqualyn Fouse et Dr Richard Levy, la Dr Fouse ayant re莽u la plus forte approbation (18,8 millions de voix)
  • Nomination de l'Auditeur : Les actionnaires ont ratifi茅 PricewaterhouseCoopers LLP en tant qu'auditeur ind茅pendant avec un soutien 茅crasant (20,2 millions de voix en faveur)
  • R茅mun茅ration des Dirigeants : Les actionnaires ont approuv茅 la r茅mun茅ration des dirigeants nomm茅s avec un fort soutien (18,7 millions de voix en faveur)
  • Fr茅quence du Vote Consultatif sur la R茅mun茅ration : Les actionnaires se sont fortement prononc茅s en faveur de votes consultatifs annuels sur la r茅mun茅ration des dirigeants (18,8 millions de voix), que le Conseil a adopt茅

Madrigal Pharmaceuticals hielt seine Jahreshauptversammlung 2025 am 20. Juni 2025 ab, bei der 20.427.421 Aktien vertreten waren (92 % der ausstehenden Aktien), womit ein Quorum erreicht wurde. Wichtige Ergebnisse sind:

  • Vorstands-Wahlen: Vier Direktoren der Klasse III wurden f眉r eine Amtszeit bis 2028 wiedergew盲hlt, darunter Julian Baker, Dr. Raymond Cheong, Dr. Jacqualyn Fouse und Dr. Richard Levy, wobei Dr. Fouse die h枚chste Zustimmung erhielt (18,8 Mio. Stimmen)
  • Bestellung des Abschlusspr眉fers: Die Aktion盲re best盲tigten PricewaterhouseCoopers LLP als unabh盲ngigen Abschlusspr眉fer mit 眉berw盲ltigender Mehrheit (20,2 Mio. Stimmen daf眉r)
  • 痴辞谤蝉迟补苍诲蝉惫别谤驳眉迟耻苍驳: Die Aktion盲re genehmigten die Verg眉tung der benannten F眉hrungskr盲fte mit starker Unterst眉tzung (18,7 Mio. Stimmen daf眉r)
  • Say-on-Pay-Frequenz: Die Aktion盲re sprachen sich deutlich f眉r j盲hrliche Beratungsabstimmungen zur Vorstandsverg眉tung aus (18,8 Mio. Stimmen), welche der Vorstand 眉bernommen hat
0001157601FALSE00011576012025-06-202025-06-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2025
____________________
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
____________________
Delaware001-3327704-3508648
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Four Tower Bridge
200 Barr Harbor Drive, Suite 200
West Conshohocken, Pennsylvania
19428
(Address of principal executive offices)(Zip Code)
(267) 824-2827
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.0001 Par Value Per ShareMDGLThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 20, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 24, 2025, the record date for the Annual Meeting, 22,203,282 shares of the Company’s common stock were issued and outstanding, of which 20,427,421 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the Annual Meeting, constituting a quorum. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

1. The Company’s stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company’s 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows:

ForWithheldBroker Non-Votes
Julian C. Baker17,144,833 1,806,070 1,476,517 
Raymond Cheong, Ph.D., M.D.18,218,687 732,216 1,476,517 
Jacqualyn A. Fouse, Ph.D.18,845,616 105,287 1,476,517 
Richard S. Levy, M.D.17,734,255 1,216,648 1,476,517 

2. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results were as follows:

ForAgainstAbstentionsBroker Non-Votes
20,230,193179,95917,2690

3. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows:

ForAgainstAbstentionsBroker Non-Votes
18,720,175208,91121,8171,476,517

4. The Company’s stockholders approved, on a non-binding, advisory basis, a frequency of every "One Year" for future advisory stockholder votes on the compensation of the Company’s named executive officers. The voting results were as follows:

One YearTwo YearsThree YearsAbstentionsBroker Non-Votes
18,863,5797,01164,05216,2611,476,517

After considering the results of the non-binding, advisory vote, the Board of Directors of the Company has determined that the Company will hold a non-binding, advisory vote on the compensation of its named executive officers every year until the next required advisory vote on the frequency of holding the advisory vote on named executive officer compensation.


2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MADRIGAL PHARMACEUTICALS, INC.
By:/s/ Mardi Dier
Name: Mardi Dier
Title: Executive Vice President and Chief Financial Officer
Date: June 20, 2025
3

Source:

FAQ

What were the voting results for MDGL's director elections at the 2025 Annual Meeting?

At MDGL's 2025 Annual Meeting, four Class III directors were re-elected: Julian C. Baker (17,144,833 votes For), Raymond Cheong, Ph.D., M.D. (18,218,687 votes For), Jacqualyn A. Fouse, Ph.D. (18,845,616 votes For), and Richard S. Levy, M.D. (17,734,255 votes For). Each director will serve until the 2028 annual meeting.

Did MDGL shareholders approve the executive compensation package in 2025?

Yes, MDGL shareholders approved the named executive officers' compensation in a non-binding, advisory vote. The measure passed with 18,720,175 votes For, 208,911 Against, and 21,817 Abstentions, with 1,476,517 Broker Non-Votes.

How often will MDGL hold advisory votes on executive compensation?

MDGL shareholders voted overwhelmingly for annual ('One Year') advisory votes on executive compensation, with 18,863,579 votes supporting annual frequency. The Board of Directors has confirmed they will hold these advisory votes every year until the next required frequency vote.

What was the shareholder participation rate at MDGL's 2025 Annual Meeting?

Out of 22,203,282 total outstanding shares, 20,427,421 shares were present in person or represented by proxy at the 2025 Annual Meeting, representing approximately 92% participation and constituting a quorum.

Did MDGL shareholders approve PricewaterhouseCoopers as their auditor for 2025?

Yes, shareholders ratified PricewaterhouseCoopers LLP as MDGL's independent registered public accounting firm for fiscal year 2025, with 20,230,193 votes For, 179,959 Against, and 17,269 Abstentions.
Stock MDGL logo
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

#1482 Ranked by Market Cap
N/A Ranked by Dividends

MDGL Latest News

Jul 30, 2025
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Jul 25, 2025
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and聽Host Webcast on August 5, 2025
Jul 22, 2025
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Jul 16, 2025
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Jul 16, 2025
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra鈩� (Resmetirom)

MDGL Latest SEC Filings

Jul 30, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 18, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing

MDGL Stock Data

6.44B
20.43M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
United States
WEST CONSHOHOCKEN